Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST])

American Heart Journal

Volumn 160, Issue 4, 2010, Pages 649-654

  Carson, Peter ^a   Fiuzat, Mona ^b,c   O'Connor, Christopher ^c   Anand, Inder ^a   Plehn, Jonathan ^d   Lindenfeld, Jo Ann ^e   Silver, Marc ^f   White, Michel ^g   Miller, Alan ^h   Davis, Gordon ^b   Robertson, Alastair D ^e   Bristow, Michael ^b,e   Gottlieb, Stephen ⁱ  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b ARCA Biopharma   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f ADVOCATE CHRIST MEDICAL CENTER   (United States)

^g MONTREAL HEART INSTITUTE   (Canada)

^h UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

ⁱ UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BUCINDOLOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; PLACEBO; VASODILATOR AGENT; WARFARIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PRIORITY JOURNAL; PROFESSIONAL STANDARD; SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; MEDICAL RECORD; MIDDLE AGED; MORTALITY; PERSONNEL; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; CLINICAL TRIALS DATA MONITORING COMMITTEES; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HOSPITAL RECORDS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RESEARCH PERSONNEL; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 77957857374     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.07.004     Document Type: Article

References (17)

1. Temple R., and Pledger G.W. The FDA's critique of the anturane reinfarction trial N Engl J Med 303 1980 1488 1492
2. Naslund U., Grip L., and Fischer-Hansen J. The impact of an end-point committee in a large multicenter, randomized, placebo-controlled clinical trial: results with and without the end point committee's final decision on end points Eur Heart J 20 1999 771 777
3. Mahaffey K.W., Roe M.T., and Dyke C.K. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial Am Heart J 143 2002 242 248
4. Cleland J.G., Erhardt L., and Murray G. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators Eur Heart J 18 1997 41 51
5. Mahaffey K.W., Harrington R.A., and Akkerhuis M. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction end points in an international clinical trial: review of the PURSUIT study Curr Control Trials Cardiovasc Med 2 2001 187 194
6. Mahaffey K.W., Harrington R.A., and Akkerhuis M. Systematic adjudication of myocardial infarction end points in an international clinical trial Curr Control Trials Cardiovasc Med 2 2001 180 186
7. Ninomiya T., Donnan G., and Anderson N. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) Stroke 40 2009 2111 2115
8. Petersen J.L., Haque G., and Hellkamp A.S. Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee Contemp Clin Trials 27 2006 260 268
9. O'Connor C.M., Carson P.E., and Miller A.B. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation Am J Cardiol 82 1998 881 887
10. Design of the Beta-Blocker Evaluation Survival Trial (BEST) The BEST Steering Committee Am J Cardiol 75 1995 1220 1223
11. Eichhorn E.J., Domanski M.J., Krause-Steinrauf H. for the BEST Investigators A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure N Engl J Med 344 2001 1659 1667
12. O'Connor C.M., Gottlieb S., and Bourque J.M. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy Am J Cardiol 95 2005 558 564
13. Solomon S.D., Wang D., and Finn P. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program Circulation 110 2004 2180 2183
14. Packer M., Califf R.M., and Konstam M.A. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation 106 2002 920 926
15. The MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
16. Bristow M.R., Saxon L.A., and Boehmer J. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure N Engl J Med 350 2004 2140 2150
17. Pogue J., Walter S.D., and Yusuf S. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs Clin Trials 6 2009 239 251